Bodegas A, Cabrera A, Sarrionaindía M J, Idígoras G, Rumoroso J R, Pérez García P, Pastor E, Galdeano J M, Sota J, Barrenetxea J I
Servicio de Cardiología, Hospital de Cruces, Baracaldo, Vizcaya.
Rev Esp Cardiol. 1994 Feb;47(2):86-91.
In order to study the efficiency of oral dose of propafenone in preventing childhood supraventricular tachycardias, we have treated 38 children without left ventricular dysfunction.
The mean age has been 8 +/- 4.7 years old. All of them had suffered at least two episodes of supraventricular tachycardia, and eleven had undergone a previous antiarrhythmic treatment. The initial dose of propafenone has been 6.5 +/- 2.1 mg/kg/24 h (in 3 doses), which has been increased in case of inefficacy.
We have not advised neither side-effects, nor proarrhythmic effects, during a follow-up of 13 +/- 6 months. Propafenone has been efficient in preventing supraventricular tachycardias in all patients. The initial dose has been efficient in 17 patients, and we have increased the initial dose up to 11.1 +/- 3.7 mg/kg/24 h in 21 patients. The mean effective dose has been 8.9 +/- 3.6 mg/kg/24 h. We stopped treatment in 14 patients after been 6 months without supraventricular tachycardias.
From our study, we conclude that propafenone has been efficient in preventing supraventricular tachycardias in childhood with a dose of 8.9 mg/kg/24 h. We have not found side-effects.
为研究口服普罗帕酮预防儿童室上性心动过速的疗效，我们对38例无左心室功能障碍的儿童进行了治疗。
平均年龄为8±4.7岁。他们均至少有过两次室上性心动过速发作，其中11例曾接受过抗心律失常治疗。普罗帕酮初始剂量为6.5±2.1mg/kg/24小时（分3次服用），无效时增加剂量。
在13±6个月的随访期间，未发现副作用及促心律失常作用。普罗帕酮对所有患者预防室上性心动过速均有效。初始剂量对17例患者有效，21例患者的初始剂量增至11.1±3.7mg/kg/24小时。平均有效剂量为8.9±3.6mg/kg/24小时。14例患者在无室上性心动过速发作6个月后停药。
根据我们的研究，我们得出结论，普罗帕酮以8.9mg/kg/24小时的剂量预防儿童室上性心动过速有效，且未发现副作用。
